LAI versus oral antipsychotic treatment of schizophrenia: A 12-month prospective study on patient's attitude towards treatment and quality of life - 13/04/16
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 2 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Résumé |
Introduction |
It is still a matter of debate whether LAI antipsychotics are able to significantly improve patient's attitude towards treatment.
Objective |
The aim of this 12-month observational study was to investigate the impact of switching antipsychotic treatment from oral to LAI formulation on patient's attitude towards treatment and quality of life.
Methods |
A total of 41 schizophrenic patients (25 males, mean age 42.10±11.88 years) were recruited. Patients were expected not to need significant changes in concomitant treatments. All patients were under a stabilized therapy with a single oral antipsychotic (either olanzapine or paliperidone) and were switched to the equivalent maintenance regimen with the long-acting formulation of the same antipsychotic (olanzapine pamoate or paliperidone palmitate). Patients were assessed before the switch (T0), and after 6 (T1) and 12 months (T2) of LAI antipsychotic treatment by means of the YMRS, MADRS, PANSS, DAI-10 and SF-36.
Results |
Our data evidenced an overall significant improvement of psychopathology, adherence and quality of life over the 12-month period (T0 vs. T2). In particular, while all of the measures significantly improved in the first semester (T0 vs. T1), only YMRS, positive PANSS and DAI-10 improved both in the first and in the second semester (T1 vs. T2), indicating an additional advantage of a prolonged LAI treatment on these clinical dimensions.
Conclusions |
The switch from oral to long-acting antipsychotic treatment may provide considerable advantages in improving patient's attitude towards (and therefore adherence to) treatment. Part of this improvement could be related with a better efficacy on psychopathology and quality of life.
Le texte complet de cet article est disponible en PDF.Plan
Vol 33 - N° S
P. S583-S584 - mars 2016 Retour au numéro
Article précédent
- LAI versus oral antipsychotic maintenance treatment of schizophrenia: A case-control study on subjective experience of treatment
- F. Pietrini, M. Spadafora, L. Tatini, G.A. Talamba, E. Burchi, E. Calderani, S. Gemignani, L. Mallardo, C. Andrisano, G. Boncompagni, M. Manetti, A. Ballerini, V. Ricca
- Catatonic schizophrenia vs anti-NMDA receptor encephalitis – A video case report
- A. Ponte, J. Gama Marques, L. Carvalhão Gil, C. Nobrega, S. Pinheiro, A. Brito
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?